search
Back to results

Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (PARTUM)

Primary Purpose

Venous Thromboembolism, Postpartum Period, Aspirin

Status
Completed
Phase
Early Phase 1
Locations
International
Study Type
Interventional
Intervention
Aspirin 81 mg
Placebo
Sponsored by
University of Calgary
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Venous Thromboembolism focused on measuring deep vein thrombosis, pulmonary embolism, postpartum, pregnancy, thrombophilia, cesarean delivery, pre-eclampsia, postpartum hemorrhage

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Study inclusion criteria includes one (or more) first order criterion or two (or more) second order criteria. A patient is still eligible if they have multiple criteria met, at the discretion of the local investigator.

ONE (or more) First Order Criteria:

  1. Known inherited thrombophilia diagnosed prior to enrolment:

    i) Heterozygous factor V Leiden, OR ii) Heterozygous prothrombin gene variant, OR iii) Protein C deficiency, OR iv) Protein S deficiency

  2. Immobilization (90% of waking hours spent in bed) for ≥7 days anytime during the antepartum period

TWO (or more) Second Order Criteria:

  1. Postpartum infection
  2. Postpartum hemorrhage (>1000 mL of blood loss, regardless of delivery mode)
  3. Pre-pregnancy BMI ≥30 kg/m2
  4. Emergency or unplanned cesarean delivery
  5. Smoking ≥5 cigarettes/day before pregnancy
  6. Pre-eclampsia
  7. Current pregnancy ending in stillbirth (pregnancy loss >20 weeks gestation)
  8. Small-for-gestational-age infant (<3rd percentile adjusted for gestational age and sex).
  9. Previous history of superficial vein thrombosis

Exclusion Criteria:

  1. More than 48 hours since delivery
  2. Received more than 2 doses of low-molecular-weight heparin (LMWH) since delivery
  3. Need for postpartum LMWH prophylaxis or systemic anticoagulation as judged by the local investigator. May include but is not limited to:

    1. Documented history of provoked or unprovoked VTE
    2. Mechanical heart valve(s)
    3. Known antiphospholipid syndrome
    4. Known high-risk inherited thrombophilia i) Antithrombin deficiency; ii) Homozygous factor V Leiden; iii) Homozygous prothrombin gene mutation; iv) Compound heterozygosity factor V Leiden and prothrombin gene mutation; v) More than one inherited thrombophilia
  4. Need for postpartum aspirin as judged by the local investigator. May include but is not limited to:

    1. Documented history of myocardial infarction
    2. Documented history of ischemic stroke or transient ischemic attack (TIA)
  5. Contraindication to aspirin including:

    1. History of known aspirin allergy
    2. Documented history of a gastrointestinal ulcer
    3. Known platelet count <50 x 109/L at any time during the current pregnancy or postpartum
    4. Active bleeding at any site, excluding normal vaginal bleeding, at the time of randomization
    5. Most recent known hemoglobin ≤70 g/L documented during the current pregnancy or postpartum
    6. Known severe hypertension (SBP >200mm/hg and/or DBP >120mm/hg) during the current pregnancy or postpartum
  6. <18 years of age
  7. Unable or refused consent

Sites / Locations

  • Foothills Medical Centre
  • British Columbia Women's Hospital & Health Centre
  • The Ottawa Hospital - General Campus
  • Mount Sinai Hospital
  • Centre Hospitalier Universitaire de Saint-Etienne
  • Rotunda Hospital
  • The Amsterdam Medical Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Aspirin

Placebo

Arm Description

Aspirin 81 mg daily for six weeks post-randomization (postpartum)

Placebo daily for six weeks post-randomization (postpartum)

Outcomes

Primary Outcome Measures

Recruitment Rate
Mean recruitment rate per center per month

Secondary Outcome Measures

Consent Rate
Proportion of eligible subjects who provide consent
Withdrawals/Loss to Follow-up
Proportion of withdrawals/loss to follow-up among participants
Study Drug Compliance
Level of compliance with study drug through participant recall and medication diary
Time Required to Obtain Site Institutional Approvals
Proportion of sites requiring >18 months to obtain all required approvals/contracts from time of delivery of all study documents.
VTE Event Rate
A more precise estimate of the VTE event rate
Bleeding Event Rate
A more precise estimate of the major and clinically relevant non-major bleeding event rate

Full Information

First Posted
November 4, 2019
Last Updated
September 8, 2023
Sponsor
University of Calgary
Collaborators
Canadian Institutes of Health Research (CIHR), Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
search

1. Study Identification

Unique Protocol Identification Number
NCT04153760
Brief Title
Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Acronym
PARTUM
Official Title
A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Evaluating Aspirin in Postpartum Women at Risk of Developing Venous Thromboembolism
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
October 7, 2020 (Actual)
Primary Completion Date
September 5, 2023 (Actual)
Study Completion Date
September 5, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Calgary
Collaborators
Canadian Institutes of Health Research (CIHR), Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The pilot PARTUM trial is a randomized, multicenter, placebo-controlled trial. Women who are at modest risk of VTE (as defined by the inclusion criteria) will be identified during pregnancy, labor and delivery and up to 48 hours postpartum. Eligible and consenting participants will be randomly assigned to one of two study arms: aspirin 81 mg daily or placebo daily for 6 weeks.
Detailed Description
The purpose of the pilot PARTUM trial is to determine whether it is feasible to conduct a larger randomized controlled trial to determine whether low-dose aspirin is efficacious and safe at preventing postpartum venous thromboembolism (VTE) in women at increased risk of VTE, compared to placebo. Given the large sample size needed to adequately power a large multicenter trial that assesses the efficacy of aspirin 81 mg versus placebo, the investigators first need to determine if it is possible to recruit enough women. If the pilot trial is successful and there are no major changes to the study design, then the secondary clinical outcomes collected in the pilot trial will be used in the analysis of the full multicenter trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Thromboembolism, Postpartum Period, Aspirin
Keywords
deep vein thrombosis, pulmonary embolism, postpartum, pregnancy, thrombophilia, cesarean delivery, pre-eclampsia, postpartum hemorrhage

7. Study Design

Primary Purpose
Prevention
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
257 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Aspirin
Arm Type
Active Comparator
Arm Description
Aspirin 81 mg daily for six weeks post-randomization (postpartum)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo daily for six weeks post-randomization (postpartum)
Intervention Type
Drug
Intervention Name(s)
Aspirin 81 mg
Other Intervention Name(s)
acetylsalicylic acid, ASA
Intervention Description
Aspirin 81 mg p.o. daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo p.o. daily
Primary Outcome Measure Information:
Title
Recruitment Rate
Description
Mean recruitment rate per center per month
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Consent Rate
Description
Proportion of eligible subjects who provide consent
Time Frame
6 months
Title
Withdrawals/Loss to Follow-up
Description
Proportion of withdrawals/loss to follow-up among participants
Time Frame
9 months
Title
Study Drug Compliance
Description
Level of compliance with study drug through participant recall and medication diary
Time Frame
6 months
Title
Time Required to Obtain Site Institutional Approvals
Description
Proportion of sites requiring >18 months to obtain all required approvals/contracts from time of delivery of all study documents.
Time Frame
24 months
Title
VTE Event Rate
Description
A more precise estimate of the VTE event rate
Time Frame
6 months
Title
Bleeding Event Rate
Description
A more precise estimate of the major and clinically relevant non-major bleeding event rate
Time Frame
6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Study inclusion criteria includes one (or more) first order criterion or two (or more) second order criteria. A patient is still eligible if they have multiple criteria met, at the discretion of the local investigator. ONE (or more) First Order Criteria: Known inherited thrombophilia diagnosed prior to enrolment: i) Heterozygous factor V Leiden, OR ii) Heterozygous prothrombin gene variant, OR iii) Protein C deficiency, OR iv) Protein S deficiency Immobilization (90% of waking hours spent in bed) for ≥7 days anytime during the antepartum period TWO (or more) Second Order Criteria: Postpartum infection Postpartum hemorrhage (>1000 mL of blood loss, regardless of delivery mode) Pre-pregnancy BMI ≥30 kg/m2 Emergency or unplanned cesarean delivery Smoking ≥5 cigarettes/day before pregnancy Pre-eclampsia Current pregnancy ending in stillbirth (pregnancy loss >20 weeks gestation) Small-for-gestational-age infant (<3rd percentile adjusted for gestational age and sex). Previous history of superficial vein thrombosis Exclusion Criteria: More than 48 hours since delivery Received more than 2 doses of low-molecular-weight heparin (LMWH) since delivery Need for postpartum LMWH prophylaxis or systemic anticoagulation as judged by the local investigator. May include but is not limited to: Documented history of provoked or unprovoked VTE Mechanical heart valve(s) Known antiphospholipid syndrome Known high-risk inherited thrombophilia i) Antithrombin deficiency; ii) Homozygous factor V Leiden; iii) Homozygous prothrombin gene mutation; iv) Compound heterozygosity factor V Leiden and prothrombin gene mutation; v) More than one inherited thrombophilia Need for postpartum aspirin as judged by the local investigator. May include but is not limited to: Documented history of myocardial infarction Documented history of ischemic stroke or transient ischemic attack (TIA) Contraindication to aspirin including: History of known aspirin allergy Documented history of a gastrointestinal ulcer Known platelet count <50 x 109/L at any time during the current pregnancy or postpartum Active bleeding at any site, excluding normal vaginal bleeding, at the time of randomization Most recent known hemoglobin ≤70 g/L documented during the current pregnancy or postpartum Known severe hypertension (SBP >200mm/hg and/or DBP >120mm/hg) during the current pregnancy or postpartum <18 years of age Unable or refused consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leslie Skeith, MD
Organizational Affiliation
University of Calgary
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marc Rodger, MD
Organizational Affiliation
McGill University Health Centre/Research Institute of the McGill University Health Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Foothills Medical Centre
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 2T9
Country
Canada
Facility Name
British Columbia Women's Hospital & Health Centre
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6H 3N1
Country
Canada
Facility Name
The Ottawa Hospital - General Campus
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1Z5
Country
Canada
Facility Name
Centre Hospitalier Universitaire de Saint-Etienne
City
Saint-Étienne
State/Province
Loire
ZIP/Postal Code
42270
Country
France
Facility Name
Rotunda Hospital
City
Dublin
ZIP/Postal Code
D01 P5W9
Country
Ireland
Facility Name
The Amsterdam Medical Centre
City
Amsterdam
State/Province
North Holland
ZIP/Postal Code
1105
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33779986
Citation
Middleton P, Shepherd E, Gomersall JC. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2021 Mar 29;3(3):CD001689. doi: 10.1002/14651858.CD001689.pub4.
Results Reference
derived

Learn more about this trial

Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

We'll reach out to this number within 24 hrs